Invivyd (IVVD) News Today → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free IVVD Stock Alerts $1.84 +0.03 (+1.66%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 1 at 9:22 AM | insidertrades.comInvivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire Sells 112,381 SharesMay 31 at 7:58 PM | marketbeat.comInvivyd, Inc. (NASDAQ:IVVD) Director Sells $186,552.46 in StockInvivyd, Inc. (NASDAQ:IVVD - Get Free Report) Director Terrance Mcguire sold 112,381 shares of the company's stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $1.66, for a total value of $186,552.46. Following the completion of the transaction, the director now directly owns 4,688,079 shares in the company, valued at $7,782,211.14. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.May 31 at 7:05 AM | globenewswire.comInvivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal AntibodiesMay 31 at 7:00 AM | globenewswire.comInvivyd Announces the Appointment of Timothy Lee as Chief Commercial OfficerMay 29, 2024 | globenewswire.comInvivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)May 26, 2024 | americanbankingnews.comInvivyd (NASDAQ:IVVD) Earns "Buy" Rating from HC WainwrightMay 24, 2024 | marketbeat.comInvivyd's (IVVD) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $15.00 price objective on shares of Invivyd in a report on Friday.May 22, 2024 | globenewswire.comInvivyd Elects Two New Independent Members to its Board of DirectorsMay 15, 2024 | marketbeat.comQ1 2025 EPS Estimates for Invivyd, Inc. (NASDAQ:IVVD) Lowered by HC WainwrightInvivyd, Inc. (NASDAQ:IVVD - Free Report) - HC Wainwright cut their Q1 2025 EPS estimates for Invivyd in a research note issued to investors on Tuesday, May 14th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of $0.02 for the quarter, down from theiMay 14, 2024 | markets.businessinsider.comStrong Buy Rating for Invivyd Amidst Potential EUA Approval and Promising Revenue ProjectionsMay 13, 2024 | msn.comInvivyd, Inc. (NASDAQ:IVVD) Q1 2024 Earnings Call TranscriptMay 13, 2024 | globenewswire.comInvivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 12, 2024 | finance.yahoo.comWith 31% stake, Invivyd, Inc. (NASDAQ:IVVD) seems to have captured institutional investors' interestMay 10, 2024 | finance.yahoo.comInvivyd Inc (IVVD) Reports Q1 2024 Financial Results: A Detailed AnalysisMay 9, 2024 | investorplace.comIVVD Stock Earnings: Invivyd Meets EPS for Q1 2024May 9, 2024 | globenewswire.comInvivyd Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 7, 2024 | globenewswire.comInvivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA FeedbackMay 3, 2024 | marketbeat.comInvivyd (IVVD) Set to Announce Quarterly Earnings on ThursdayInvivyd (NASDAQ:IVVD) will be releasing earnings after the market closes on Thursday, May 9, Zacks reports.May 2, 2024 | globenewswire.comInvivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business HighlightsApril 30, 2024 | globenewswire.comInvivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash PositionApril 20, 2024 | morningstar.comInvivyd Inc Ordinary SharesApril 15, 2024 | globenewswire.comInvivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™April 15, 2024 | globenewswire.comInvivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™April 12, 2024 | msn.comInvivyd appoints Jeremy Gowler as interim CEOApril 12, 2024 | markets.businessinsider.comInvivyd Appoints Jeremy Gowler As Interim CEO As Dave Hering ResignsApril 12, 2024 | globenewswire.comInvivyd Announces CEO TransitionApril 8, 2024 | ca.news.yahoo.comCanadian farmers demand relief from price on carbon imposed by federal governmentApril 5, 2024 | finanznachrichten.deInvivyd Provides PEMGARDA Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 MillionApril 4, 2024 | finance.yahoo.comInvivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 MillionApril 4, 2024 | globenewswire.comInvivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 MillionApril 1, 2024 | marketbeat.comInvivyd (NASDAQ:IVVD) Shares Gap Up to $4.44Invivyd (NASDAQ:IVVD) Shares Gap Up to $4.44March 28, 2024 | benzinga.comInvivyd: Q4 Earnings InsightsMarch 28, 2024 | investorplace.comIVVD Stock Earnings: Invivyd Misses EPS for Q4 2023March 28, 2024 | globenewswire.comInvivyd Reports Full Year 2023 Financial Results and Recent Business HighlightsMarch 27, 2024 | msn.comMorgan Stanley ups Invivyd to overweight, cites FDA EUA decisionMarch 26, 2024 | markets.businessinsider.comMaintaining Buy on Invivyd: Pemgarda’s EUA and Market Growth PotentialMarch 26, 2024 | marketbeat.comInvivyd (NASDAQ:IVVD) Upgraded by Morgan Stanley to OverweightMorgan Stanley upgraded shares of Invivyd from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $4.00 to $10.00 in a research note on Tuesday.March 26, 2024 | markets.businessinsider.comInvivyd’s PEMGARDA: Strong Buy Rating on FDA EUA and Strategic Market PositioningMarch 26, 2024 | msn.comFDA Gives Emergency Use Nod To Invivyd's Antibody To Prevent COVID-19 Infection In Adults, Adolescents With Weak Immune SystemMarch 23, 2024 | finanznachrichten.deInvivyd Announces FDA Authorization for Emergency Use of PEMGARDA (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19March 22, 2024 | stockhouse.comInvivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical TrialMarch 22, 2024 | msn.comInvivyd stock soars on FDA EUA for COVID-19 prophylaxis drugMarch 22, 2024 | marketbeat.comTrading was temporarily halted for "IVVD" at 03:03 PM with a stated reason of "LULD pause." Trading set to resume at 04:03 PM. March 22, 2024 | globenewswire.comInvivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical TrialMarch 22, 2024 | globenewswire.comInvivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19March 22, 2024 | marketbeat.comTrading was temporarily halted for "IVVD" at 01:03 PM with a stated reason of "News pending."March 19, 2024 | marketbeat.comCitigroup Inc. Sells 1,817,981 Shares of Invivyd, Inc. (NASDAQ:IVVD)Citigroup Inc. lessened its stake in shares of Invivyd, Inc. (NASDAQ:IVVD - Free Report) by 78.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 509,165 shares of the company's stock after selling 1,817,981March 18, 2024 | edition.cnn.comLigand Pharmaceuticals IncorporatedMarch 13, 2024 | seekingalpha.comPiper Sandler upgrades Solid Biosciences to overweightMarch 7, 2024 | marketbeat.comFmr LLC Sells 1,878,412 Shares of Invivyd, Inc. (NASDAQ:IVVD)Fmr LLC lowered its holdings in Invivyd, Inc. (NASDAQ:IVVD - Free Report) by 18.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,060,939 shares of the company's stock after selling 1 Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Email Address The Only Energy Play You Should Be Looking At (Ad)Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy. Click here to get all the information about it. IVVD Media Mentions By Week IVVD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IVVD News Sentiment▼0.440.76▲Average Medical News Sentiment IVVD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IVVD Articles This Week▼72▲IVVD Articles Average Week Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GLUE News Today MCRB News Today KNTE News Today BLUE News Today KRON News Today ICVX News Today SRRK News Today PRME News Today RGNX News Today CRGX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IVVD) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsWho are Nvidia’s New Silent Partners?Weiss Ratings[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
